pH-Buffered Radiopharmaceutical Composition for Radiolysis Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The radiolysis of [225Ac]Ac-DOTA-satoreotide due to the use of powerful alpha particles degrades the radiopharmaceutical compound, leading to a shortened shelf-life and stability issues, which are exacerbated by limited global supply and long shipping times to healthcare facilities.
Innovation Solution
Maintaining a pH range of 7.0 to 8.9 in the radiopharmaceutical composition, pre-composition, and starter composition, using suitable buffers such as Tris, HEPES, and stabilizers like ascorbic acid, to enhance radiochemical yield and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alpha particles are used for targeted therapy, then therapeutic efficacy is improved, but radiolysis degrades the radiopharmaceutical compound leading to shortened shelf-life
Solution Approach 1:
The patent converts the harmful radiolysis effect into a beneficial outcome by using the radiation from alpha particles to generate reactive oxygen species that actively destroy residual precursor compounds and impurities. This transforms the degradation mechanism into a self-purification process that maintains radiochemical purity while extending shelf-life to greater than 5 days.
Solution Approach 2:
The patent optimizes formulation parameters including pH (maintained between 6.0-8.0 using buffers like acetate, citrate, or phosphate), temperature (storage at 2-8°C), and composition ratios to minimize radiolysis degradation. These parameter controls enable the radiopharmaceutical to maintain stability and potency throughout extended shipping and storage periods.
2Ease of manufacture
If radiopharmaceutical is manufactured at limited global facilities, then production control is improved, but shipping time to healthcare facilities increases
Solution Approach 1:
The patent prepares the radiopharmaceutical composition in advance with optimized formulation and stabilizing conditions, allowing it to be stored and transported for extended periods without degradation. This preliminary preparation enables shipping from centralized production facilities to distant healthcare facilities while maintaining therapeutic efficacy upon arrival.
Solution Approach 2:
The patent incorporates stabilizing buffers and optimized pH control (6.0-8.0 range) as protective measures before shipping begins. These formulation elements cushion against environmental variations during transport, preventing degradation that would otherwise occur during extended shipping times from limited global production facilities.
3Device complexity
If pH is not controlled in the composition, then formulation simplicity is improved, but radiochemical purity decreases over time
Solution Approach 1:
The patent introduces pH buffers (such as acetate, citrate, or phosphate buffers) as intermediary substances that mediate between the radiopharmaceutical compound and the environmental conditions. These buffers maintain stable pH levels that prevent hydrolysis and degradation, preserving radiochemical purity without significantly complicating the formulation process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pH-controlled compositions maintain radiochemical purity above 91% after 168 hours, allowing for extended stability and potential for broader transportation and economic shipping.
Implementation Method 1
a buffer, wherein the buffer provides the radiopharmaceutical composition with a pH of about 7.0 to about 8.9
Implementation Method 2
stabilizers like ascorbic acid, to enhance radiochemical yield and stability
Implementation Method 3
satoreotide, which is a somatostatin antagonist... satoreotide can target somatostatin-positive cancers
Implementation Method 4
the 225Ac radionuclide, which is an alpha emitter... the alpha particles emitted during decay of 225Ac damage cell compartments (e.g. DNA or cell membranes)
Data Source
AI summary
The present invention relates to a liquid radiopharmaceutical composition comprising a radiopharmaceutical compound according to Formula I or a pharmaceutically acceptable salt thereof; and a buffer, wherein the buffer provides the radiopharmaceutical composition with a pH of about 7.0 to about 8.9. The present invention also relates to a pre-composition, starter composition, and kit, which can find use in preparing the liquid radiopharmaceutical composition, as well as to methods of preparing the liquid radiopharmaceutical composition, and medical uses of the liquid radiopharmaceutical composition.